'Groundbreaking' Lung Cancer Trial Shows Survival Benefits

Adding durvalumab as consolidation treatment following concurrent chemoradiation adds 2 years of life and increases progression-free survival by 24% compared with placebo, in patients with limited stage small cell lung cancer .

"ADRIATIC is the first positive, global phase 3 trial of immunotherapy in limited stage SCLC," said Lauren Byers, MD, the discussant in the session. After a median follow-up of 3 years, there was a median OS of 55.9 months in the durvalumab-treated patients compared with 33.4 months in the placebo arm , and, at a median follow-up of 2 years, there was median PFS of 16.6 months vs 9.2 months respectively ."This study had a very good safety profile," said Dr Spigel, who is also a medical oncologist and the chief scientific officer at Sarah Cannon Research Institute in Nashville, Tennessee, during his presentation.

Toby Campbell, MD, a thoracic oncologist, who is professor and chief of Palliative Care at the University of Wisconsin, in Madison, Wisconsin, agrees.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lung cancer treatment: Pfizer's Lorbrena extends life in some non-small cell lung cancersKaitlin Sullivan is a contributor for NBCNews.com who has worked with NBC News Investigations. She reports on health, science and the environment and is a graduate of the Craig Newmark Graduate School of Journalism at City University of New York.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Pfizer's drug for advanced lung cancer shows promising long-term trial resultsThe company's medicine helped patients live longer without seeing their cancer progress, as most of them experienced that benefit for over five years.
Source: CNBC - 🏆 12. / 72 Read more »

Groundbreaking human trial for tooth regeneration drug set to beginThe world's first clinical trial of a drug designed to regenerate human teeth is slated to start in a few months, following promising results from animal studies. If successful, the revolutionary treatment could be available commercially by 2030.
Source: WashTimes - 🏆 235. / 63 Read more »

Groundbreaking New Study Reveals That Statins Could Prevent CancerScience, Space and Technology News 2024
Source: SciTechDaily1 - 🏆 84. / 68 Read more »

Trials show ‘unprecedented’ pill slowing lung cancer in 60% of patientsLorlatinib is a third-generation ALK inhibitor used as standard first-line treatment for patients with ALK-positive NSCLC or lung cancer.
Source: IntEngineering - 🏆 287. / 63 Read more »